Griffonia

This is the most-studied indication and the origin of Griffonia’s reputation. A Cochrane review of 5-HTP and tryptophan for depression found only two trials (64 patients total) of adequate quality; pooled, they favoured the precursors over placebo (Peto OR ≈ 4.1, 95% CI 1.3–13.2), but the reviewers judged the evidence insufficient because of small size and probable publication bias among ~100 excluded low-quality studies ^{1,2Reference 1Shaw K et al. · 2001Systematic reviewTryptophan and 5-hydroxytryptophan for depression — systematic reviewView study →Reference 2Shaw K et al. · 2002Meta-analysisAre tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysisView study →}. Later randomised trials are more encouraging but still small and often use active comparators rather than placebo: 5-hydroxytryptophan matched fluoxetine over 8 weeks in first-episode depression (n=60) ^{3Reference 3Jangid P et al. · 2013RCTComparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in first depressive episode — randomised double-blind trialView study →} and performed comparably to fluvoxamine ^{4Reference 4Pöldinger W et al. · 1991RCTA functional-dimensional approach to depression: 5-hydroxytryptophan versus fluvoxamine — randomised multicentre trialView study →}, while a small placebo-controlled crossover trial in Parkinson’s disease (n=25, 50 mg/day) reported improvement in depressive and apathy scores ^{5Reference 5Meloni M et al. · 2020RCTEfficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson’s disease — randomised, double-blind, placebo-controlled crossover trialView study →}. Every one of these used purified 5-HTP; none tested whole Griffonia seed extract.

Gap: no adequately powered, modern, placebo-controlled trial; and no depression trial has used the whole-seed extract that consumers actually buy.

5-HTP’s satiety effect has the most internally consistent human signal. In a double-blind RCT, obese adults given 5-hydroxytryptophan 900 mg/day over two 6-week periods lost significant weight, reduced carbohydrate intake and reported early satiety, both with and without a prescribed diet ^{8Reference 8Cangiano C et al. · 1992RCTEating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan — randomised controlled trialView study →}. A separate double-blind RCT in overweight women used a plant-extract sublingual spray naturally containing 5-HTP and reported increased satiety with confirmed 5-HTP bioavailability (urinary 5-HIAA) over 8 weeks ^{9Reference 9Rondanelli M et al. · 2009RCTSatiety and amino-acid profile in overweight women after a natural plant-extract (5-hydroxytryptophan) sublingual spray — randomised, double-blind, placebo-controlled trialView study →} — one of the few human trials to use a botanical preparation rather than the pure molecule. The mechanism (post-prandial serotonergic satiety signalling) is coherent, but sample sizes are small and long-term weight-maintenance data are absent.

Gap: short trials, small samples, no durability data; nausea at the higher (900 mg) doses limits tolerability.

Two Italian studies underpin this use. A double-blind, placebo-controlled trial in 50 patients with primary fibromyalgia found that 5-hydroxytryptophan significantly improved tender-point count, pain, sleep, anxiety and fatigue, with only mild transient side-effects ^{6Reference 6Caruso I et al. · 1990RCTDouble-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome — randomised controlled trialView study →}; a subsequent 90-day open study in another 50 patients reported significant improvement across the same variables and sustained effect, with ~30% reporting (mostly minor) side-effects ^{7Reference 7Sarzi Puttini P · 1992Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open studyView study →}. The signal is consistent and the mechanism plausible given serotonin’s role in central pain modulation and sleep, but the evidence is two small studies from a single group, one uncontrolled, and now three decades old.

Gap: no replication outside the original investigators, no placebo-controlled confirmation since 1990, and no whole-extract data.

The clearest human anxiety signal is a challenge-model RCT: 200 mg L-5-hydroxytryptophan significantly blunted the reaction to a 35% CO₂ panic challenge in 24 panic-disorder patients (subjective anxiety, panic-symptom score and number of attacks) but not in healthy controls ^{10Reference 10Schruers K et al. · 2002RCTAcute L-5-hydroxytryptophan administration inhibits carbon-dioxide-induced panic in panic disorder patients — randomised controlled trialView study →}. An older double-blind comparison of 5-HTP, clomipramine and placebo in anxiety disorders provides supporting but weaker evidence ^{11Reference 11Kahn RS · 1987RCTEffect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placeboView study →}. Uniquely for this indication, there is also a study using the actual herb: Griffonia seed extract (10 and 25 mg/kg) increased time in the light compartment in a rat dark–light test, the first published in-vivo evidence that the extract itself has anxiolytic activity ^{17Reference 17Carnevale G et al. · 2011AnimalAnxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats — animal modelView study →}. A companion rat study is a caution flag rather than a benefit — the same extract reduced receptive/proceptive sexual behaviour in female rats at higher doses ^{18Reference 18Carnevale G et al. · 2010AnimalGriffonia simplicifolia negatively affects sexual behavior in female rats — animal modelView study →}.

Gap: human data are a single acute challenge model, not a treatment trial; the direct-herb evidence is rodent-only.

Migraine is where the evidence is genuinely mixed. In adults, an RCT of 124 migraineurs found 5-hydroxytryptophan improved attacks in ~71% of patients — comparable to methysergide (~75%) and better tolerated — but this used an active comparator with no placebo arm ^{12Reference 12Titus F et al. · 1986RCTTitus F, Dávalos A, Alom J, Codina A. (1986). 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine — randomised clinical trial. European Neurology. https://pubmed.ncbi.nlm.nih.gov/3536521/View study →}, and a separate trial reported it comparable to propranolol. The key limiter is the paediatric evidence: a double-blind, placebo-controlled crossover trial in children (5 mg/kg/day) found that both 5-HTP and placebo reduced migraine index, with no significant difference between them ^{13Reference 13Santucci M et al. · 1986RCTL-5-hydroxytryptophan versus placebo in childhood migraine prophylaxis — double-blind crossover studyView study →}. So the adult “positive vs active drug” picture is undercut by a null result against placebo in children.

Gap: no adult placebo-controlled trial; the one rigorous placebo comparison (paediatric) was negative, consistent with a large placebo response in migraine.

The sleep rationale is mechanistic: serotonin is the biosynthetic precursor to melatonin, so raising serotonin synthesis is argued to support sleep onset ^{16Reference 16Birdsall TC · 1998ReviewBirdsall TC. (1998). 5-Hydroxytryptophan: a clinically-effective serotonin precursor — review. Alternative Medicine Review. https://pubmed.ncbi.nlm.nih.gov/9727088/View study →}. Direct human evidence is thin and old — early work showed 5-hydroxytryptophan alters sleep architecture (notably REM) in normal subjects ^{14Reference 14Wyatt RJ et al. · 1971Clinical trialEffects of 5-hydroxytryptophan on the sleep of normal human subjects — clinical trialView study →} — but there is no modern, placebo-controlled insomnia trial of Griffonia extract, and the appetite/mood trials did not use validated sleep endpoints as primary outcomes. Sleep improvement is often reported as a secondary benefit within fibromyalgia and mood studies rather than tested directly.

Gap: no dedicated insomnia RCT of the extract; the claim leans on mechanism and secondary outcomes.

Antioxidant activity is a property of the seed extract measured in the test tube, not a clinical outcome. A metabolomics study characterising Griffonia seed extracts across solvents (water, acetone, methanol, ethanol) and extraction methods reported antioxidant, antiproliferative and antimicrobial activity, with radical-scavenging capacity tracking the flavonoid and flavan-3-ol content that acetone/ethanol extracted best ^{19Reference 19Mannino G et al. · 2023In vitroBiological activity and metabolomics of Griffonia simplicifolia seeds extracted with different methodologies — in vitroView study →}. This is useful for understanding the extract’s chemistry but says nothing about systemic antioxidant effects at ingested doses.

Gap: in-vitro only, solvent- and method-dependent, no bioavailability or human data; the effect may not survive digestion at realistic doses.

This is a newer, herb-specific line of work. A 2025 study optimised 5-HTP yield from Griffonia seed by high-power ultrasonic extraction and tested the extract in a mouse model of vulvovaginal candidiasis, reporting reduced infection and inflammation attributed to serotonin’s known immunomodulatory activity, then formulated it as a vaginal preparation ^{20Reference 20Puccetti M et al. · 2025AnimalGriffonia simplicifolia seeds extract rich in 5-hydroxy-L-tryptophan reduces infection and inflammation in a mouse model of vulvovaginal candidiasis — animal modelView study →}. It is a single, mechanistically-motivated animal study rather than a body of evidence, and the effect is inferred to run through serotonin signalling rather than a direct antifungal action.

Gap: one animal model, one group; no human data and no confirmation that the immunomodulatory effect is clinically meaningful.

Antitumour interest is entirely preclinical and cell-line based. A hydroalcoholic (ethanol/water 70:30) Griffonia seed extract showed cytotoxic and antimetastatic activity against osteosarcoma cell lines and was explored for interaction with chemotherapy targeting ^{21Reference 21Bellavia D et al. · 2026In vitroAntimetastatic effects of a Griffonia simplicifolia seed extract in osteosarcoma cell lines — in vitroView study →}, and the metabolomics study above also reported antiproliferative activity in vitro ^{19Reference 19Mannino G et al. · 2023In vitroBiological activity and metabolomics of Griffonia simplicifolia seeds extracted with different methodologies — in vitroView study →}. These are early screening results in cultured cells; there is no animal tumour-model or human evidence, and the concentrations used in vitro may not be achievable systemically.

Gap: cell-line only, no in-vivo tumour data, no pharmacokinetic bridge to achievable human exposures.

Griffonia is dosed by its 5-hydroxytryptophan (5-HTP) content, and its safety profile is essentially that of 5-HTP: generally well tolerated at common doses, with nausea and gastrointestinal upset the most frequent, dose-related complaints ^{22Reference 22Das YT et al. · 2004ReviewSafety of 5-hydroxy-L-tryptophan — reviewView study →}. The principal risk is serotonergic: it should not be combined with SSRIs, SNRIs, MAOIs, triptans, tramadol or other serotonergic agents (including dextromethorphan, linezolid and St John’s Wort) without medical supervision, because of the risk of serotonin syndrome ^{22Reference 22Das YT et al. · 2004ReviewSafety of 5-hydroxy-L-tryptophan — reviewView study →}. A distinct historical concern is contamination — a family of trace contaminants (“Peak X”, characterised as 4,5-tryptophan-dione and related species) has been detected in commercial 5-HTP and is chemically related to the contaminant implicated in the 1989 L-tryptophan eosinophilia-myalgia syndrome (EMS) outbreak; no definitive causal EMS case has been established for 5-HTP, but the signal argues for pharmaceutical-grade, tested material ^{22,23,24Reference 22Das YT et al. · 2004ReviewSafety of 5-hydroxy-L-tryptophan — reviewView study →Reference 23Klarskov K et al. · 1999Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophanView study →Reference 24Klarskov K et al. · 2003Structural characterization of a case-implicated contaminant, “Peak X,” in commercial 5-hydroxytryptophanView study →}. Some formulations add carbidopa to reduce peripheral decarboxylation and nausea; this raises CNS bioavailability and its own interaction considerations. Discontinue before scheduled surgery.

Herb–drug interaction assessment here is pharmacodynamic (serotonergic), not pharmacokinetic: no dedicated CYP450 or herb–drug metabolic interaction study of Griffonia extract was identified. The absence of such studies should not be read as evidence of safety.